WO2003105762A3 - Treating disease using radium-225 - Google Patents

Treating disease using radium-225 Download PDF

Info

Publication number
WO2003105762A3
WO2003105762A3 PCT/US2003/018634 US0318634W WO03105762A3 WO 2003105762 A3 WO2003105762 A3 WO 2003105762A3 US 0318634 W US0318634 W US 0318634W WO 03105762 A3 WO03105762 A3 WO 03105762A3
Authority
WO
WIPO (PCT)
Prior art keywords
radium
treating disease
chelator
peptide
association
Prior art date
Application number
PCT/US2003/018634
Other languages
French (fr)
Other versions
WO2003105762A2 (en
Inventor
Kenneth R Givens
Original Assignee
Actinium Pharmaceuticals Ltd
Kenneth R Givens
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actinium Pharmaceuticals Ltd, Kenneth R Givens filed Critical Actinium Pharmaceuticals Ltd
Priority to AU2003248679A priority Critical patent/AU2003248679A1/en
Publication of WO2003105762A2 publication Critical patent/WO2003105762A2/en
Publication of WO2003105762A3 publication Critical patent/WO2003105762A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies

Abstract

A method of treating disease, e.g., bone cancer, by the administration of a composition comprising radium-225, for example, radium chloride. The radium-225 can be used in the form of a cationic species, in association with a chelator, or in association with another type of carrier (for example, a molecule, an antibody, a peptide, a protein analog, a chelator-­antibody combination, a peptide-antibody combination, an associated fullerene compound, or a lipid).
PCT/US2003/018634 2002-06-14 2003-06-12 Treating disease using radium-225 WO2003105762A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003248679A AU2003248679A1 (en) 2002-06-14 2003-06-12 Treating disease using radium-225

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38880802P 2002-06-14 2002-06-14
US60/388,808 2002-06-14

Publications (2)

Publication Number Publication Date
WO2003105762A2 WO2003105762A2 (en) 2003-12-24
WO2003105762A3 true WO2003105762A3 (en) 2004-03-04

Family

ID=29736547

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/018634 WO2003105762A2 (en) 2002-06-14 2003-06-12 Treating disease using radium-225

Country Status (2)

Country Link
AU (1) AU2003248679A1 (en)
WO (1) WO2003105762A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1763372B1 (en) 2004-06-25 2016-11-30 The European Union, represented by the European Commission Radionuclides for medical use
EP3316871A4 (en) 2015-06-30 2019-02-20 The Trustees of Columbia University in the City of New York Talc-bound compositions and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015768A1 (en) * 1992-02-11 1993-08-19 Nycomed Salutar, Inc. Use of fullerenes in diagnostic and/or therapeutic agents
US5248498A (en) * 1991-08-19 1993-09-28 Mallinckrodt Medical, Inc. Fullerene compositions for magnetic resonance spectroscopy and imaging
US5922302A (en) * 1993-05-17 1999-07-13 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates
US6143274A (en) * 1986-01-23 2000-11-07 Tweedle; Michael F. Method for imaging and radiopharmaceutical therapy using 1-substituted-4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US6296831B1 (en) * 1998-04-10 2001-10-02 Battelle Memorial Institute Stimulus sensitive gel with radioisotope and methods of making
US6338835B1 (en) * 1997-06-03 2002-01-15 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143274A (en) * 1986-01-23 2000-11-07 Tweedle; Michael F. Method for imaging and radiopharmaceutical therapy using 1-substituted-4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5248498A (en) * 1991-08-19 1993-09-28 Mallinckrodt Medical, Inc. Fullerene compositions for magnetic resonance spectroscopy and imaging
WO1993015768A1 (en) * 1992-02-11 1993-08-19 Nycomed Salutar, Inc. Use of fullerenes in diagnostic and/or therapeutic agents
US5922302A (en) * 1993-05-17 1999-07-13 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates
US6338835B1 (en) * 1997-06-03 2002-01-15 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
US6296831B1 (en) * 1998-04-10 2001-10-02 Battelle Memorial Institute Stimulus sensitive gel with radioisotope and methods of making

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GOLDMAN ET AL., TRANS. ANS, vol. 50, November 1985 (1985-11-01), pages 7 - 8, XP002970788 *
WASHIYAMA ET AL.: "Biodistribution of Ra-225 and their daughter nuclides in neptunium series", INT. SYMP. BIO-TRACE ELEM., 2002, XP002970789 *

Also Published As

Publication number Publication date
AU2003248679A8 (en) 2003-12-31
AU2003248679A1 (en) 2003-12-31
WO2003105762A2 (en) 2003-12-24

Similar Documents

Publication Publication Date Title
UA85993C2 (en) Conjugate of a bacterial superantigen and antibody moiety, pharmaceutical composition containing thereof and method for treatment of cancer in mammals
DK1161452T3 (en) Covalently linked insulin dimers
AU2002350592A1 (en) Ph-sensitive polymer
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
PL336704A1 (en) Multivalent vaccine containing a mixed carrier
WO2004076644A3 (en) A composition for delivering an agent to a target cell and uses thereof
DE60030741D1 (en) CHINAZOLINE COMPOUNDS AS A REMEDY
AU2003217055A1 (en) Protein for use in hypoxia related conditions
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
RS20110024A (en) Crypto blocking antibodies and their use
AU3438900A (en) Use of trehalose for stabilising a liquid vaccine
PH12013500123A1 (en) Hemiasterlin derivatives and uses thereof
SE9901875D0 (en) Novel compounds
IL159388A0 (en) Improved chelator conjugates
WO2003104425A3 (en) Novel stable anti-cd22 antibodies
DE60134274D1 (en) Complex enthaltend modafinil und cyclodextrin
MXPA04003674A (en) Improved use of antitumoral compound in cancer therapy.
HK1040983A1 (en) Quinones for treatment of diseases.
ATE240303T1 (en) 1,2,4-TRIAZOLE-3-THIONE COMPOUNDS
GB9907571D0 (en) Compounds
DE60003943D1 (en) TRIMEGESTONE CONTAINING PHARMACEUTICAL COMPOSITIONS
NZ510154A (en) A tumour antigen protein and gene therefor, tumour antigen peptides and derivatives thereof in medicaments and prophylactics
EP1185276A4 (en) Isophosphoramide mustard analogs and use thereof
WO2003105762A3 (en) Treating disease using radium-225
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP